{"id":"fecal-filtrate-transplantation","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (abdominal discomfort, bloating, diarrhea)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL6068500","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic approach involves transferring filtered microbial byproducts and metabolites (rather than whole bacteria) from healthy donor feces to patients with dysbiotic conditions. The filtrate contains short-chain fatty acids, secondary bile acids, and other microbial metabolites that restore eubiotic conditions, strengthen intestinal epithelial tight junctions, and modulate local and systemic immune responses. By reconstituting the metabolic output of a healthy microbiome without transplanting live organisms, it aims to achieve therapeutic benefit with potentially reduced safety concerns compared to whole fecal microbiota transplantation.","oneSentence":"Fecal filtrate transplantation restores beneficial microbial metabolites and immune-modulating compounds from healthy donor stool to rebalance the recipient's gut microbiome and intestinal barrier function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:19.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (recurrent or refractory)"},{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"}]},"trialDetails":[{"nctId":"NCT03843385","phase":"PHASE3","title":"Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis","status":"RECRUITING","sponsor":"Andreas Stallmach","startDate":"2023-01-31","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":129},{"nctId":"NCT07240181","phase":"","title":"OPTImization of Inflammatory Bowel Disease Treatment Through Understanding of Gut VIRome Heterogeneity","status":"NOT_YET_RECRUITING","sponsor":"Andreas Munk Petersen","startDate":"2025-12-01","conditions":"IBD (Inflammatory Bowel Disease), Crohns Disease, Colitis Ulcerative","enrollment":40},{"nctId":"NCT02970877","phase":"PHASE2","title":"Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients","status":"COMPLETED","sponsor":"Johane Allard","startDate":"2017-03-01","conditions":"Obesity, Morbid, Insulin Resistance","enrollment":29},{"nctId":"NCT03806803","phase":"PHASE2","title":"Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2019-03-21","conditions":"Clostridia Difficile Colitis, Clostridium Difficile Diarrhea","enrollment":138},{"nctId":"NCT06398379","phase":"NA","title":"Virus as Treatment of C. Difficile Infection (VISION)","status":"NOT_YET_RECRUITING","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2024-05-01","conditions":"Clostridium Difficile Infections","enrollment":40},{"nctId":"NCT04960306","phase":"PHASE3","title":"Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection","status":"UNKNOWN","sponsor":"University of Pecs","startDate":"2023-11-01","conditions":"Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection","enrollment":238},{"nctId":"NCT03802461","phase":"PHASE2, PHASE3","title":"Effectiveness of Fecal Flora Alteration for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization","status":"SUSPENDED","sponsor":"Susy Hota","startDate":"2019-03-22","conditions":"Infection","enrollment":40},{"nctId":"NCT03279224","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder","status":"UNKNOWN","sponsor":"Valerie Taylor","startDate":"2018-01-01","conditions":"Bipolar Depression","enrollment":35},{"nctId":"NCT03268213","phase":"EARLY_PHASE1","title":"Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2013-11","conditions":"Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis","enrollment":12},{"nctId":"NCT03353506","phase":"PHASE2","title":"Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection","status":"COMPLETED","sponsor":"Dina Kao","startDate":"2018-02-14","conditions":"Enterocolitis, Recurrent Clostridium Difficile Infection","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fecal filtrate transplantation","genericName":"Fecal filtrate transplantation","companyName":"University of Pecs","companyId":"university-of-pecs","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fecal filtrate transplantation restores beneficial microbial metabolites and immune-modulating compounds from healthy donor stool to rebalance the recipient's gut microbiome and intestinal barrier function. Used for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}